It's a possibility after the drug is approved. Assuming Leo is ready to partner Brilacidin's platform after successful oral B-IBD and B-COVID19 phase 2 trials, BP needs to consider more important factors such as cost of phase 3 trials, length to market including time of phase 3 trials for all indications plus FDA review period, and how much time is left in the patent after approval.